USFDA Issues Warning Letter To Wockhardt's Ankleshwar Plant
New Delhi: The US Food and Drug Administration (USFDA) has issued a warning letter to Wockhardt for violating current good manufacturing practice norms, including its failure to ensure proper clothing for workers at its Ankleshwar plant in Gujarat.
In the letter to Wockhardt Chairman and Group CEO Habil Khorakiwala, the USFDA said inspectors during inspection from December 7 to 15, 2015, found "significant violations" of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals as well as for active pharmaceutical ingredients (API).
USFDA has already banned import of products from the facility into the US market since August 5, 2016.
Elaborating on the violations at the plant, USFDA noted that the company failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination.
"Our investigator observed employees working in gowns that had unravelled stitching extending from hoods, zippers, and pants. Your firm approved these gowns for operations...you should have discarded these garments," it noted.
The other violations include the firm's failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile.
"Under dynamic conditions, air did not sufficiently sweep across and away from sterile connections, so the sterility of any product processed under these conditions could be compromised," USFDA said.
Besides, the inspectors identified multiple aseptic technique breaches during aseptic connection of the equipment.
"Your equipment design and aseptic processing operator competencies appear to contribute to the lack of unidirectionality," the health regulator said.
Also, the firm failed to ensure that laboratory records included complete data derived from all tests necessary to assure compliance with established specifications and standards, USFDA said.
The firm also failed to exercise appropriate control over computer or related systems to assure that only authorised personnel institute changes in master production and control records.
Commenting on the API production issues, USFDA said the company failed "to record activities at the time they are performed, and destruction of original records".
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.